Sarepta Therapeutics Inc
SRPT
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
787.7% upsideUndervalued by 787.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.85 Billion |
|---|---|
| Enterprise Value | $2.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.13 |
| Beta | 0.21 |
| Outstanding Shares | 104,988,000 |
Return
| Return on Equity | -4.27% |
|---|---|
| Return on Assets | -2.02% |
| Return on Invested Capital | -2.87% |
Valuation & Multiples
| P/E Ratio | 28.29 |
|---|---|
| PEG | -16.26 |
| Price to Sales | 0.86 |
| Price to Book Ratio | 1.23 |
| Enterprise Value to Revenue | 1.25 |
| Enterprise Value to EBIT | -35.62 |
| Enterprise Value to Net Income | -43 |
| Total Debt to Enterprise | 0.49 |
| Debt to Equity | 0.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9951▼ 33.22% |
|---|---|
| Total Calls | 3,682,765▲ 3.07% |
| Total Puts | 3,664,600▼ 22.73% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.73%▲ 4.54% |
|---|---|
| Total Invested | $2.22B▲ 10.38% |
| Investors Holding | 367▼ 21.00% |
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...
Relevant Senate Committees
This committee provides the official revenue estimates for all tax bills, acting as a critical gatekeeper for fiscal policy. Its expertise directly influences 'corporate tax structures' and the 'overall tax burden' on all industries, including pharmaceuticals like Sarepta.
This powerful committee controls 'taxation' and 'entitlement spending,' directly impacting Sarepta's profitability through corporate tax policy and revenue streams through Medicare pricing, which is a massive payer for pharmaceutical products.
This committee directly allocates federal spending. Its subcommittees determine precise funding for the FDA, NIH, VA, and defense programs (like the Defense Threat Reduction Agency), all of which directly impact Sarepta's regulatory environment, research funding, and market access.
This committee directly regulates the FDA (drug approval, safety) and the NIH (medical research funding), which are paramount to Sarepta's drug development and commercialization success. It directly drives stock performance in the pharmaceutical sector.
This committee's oversight of 'intellectual property' is crucial for pharmaceutical companies whose business model relies on patents. Its role in 'antitrust laws' also impacts potential mergers and acquisitions in the biotech sector.
This committee oversees the Department of Defense and authorizes the NDAA. Sarepta previously won a contract with the Defense Threat Reduction Agency, making this committee's R&D funding and procurement decisions directly relevant to potential future defense-related medical contracts.
The Department of Veterans Affairs is a major healthcare provider and drug purchaser. This committee's funding decisions directly impact government healthcare contractors and the market for pharmaceutical companies selling to the VA.
Explicitly mentioned as impacting 'biotech stocks,' members receive classified briefings on global threats, which could include biological threats or medical advancements with national security implications. Sarepta's past contract with the Defense Threat Reduction Agency also indicates potential relevance.